Royal Bank Of Canada Has Lowered Expectations for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price

Key Points

• Royal Bank of Canada lowered its price target on Eyepoint from $39 to $37 but kept an outperform rating, with the $37 target implying roughly a 175% upside from the current share price (~$13.44).
• The analyst consensus remains a Buy with an average target of $31.80, though views are mixed — several firms (Citigroup, HC Wainwright, Chardan) have raised targets while Weiss Ratings reiterated a sell.
• Eyepoint reported a quarterly loss of ($0.99) per share versus ($0.79) expected, posted a very negative net margin (739.39%) and negative ROE, trades at $13.44 with a $1.13B market cap, and analysts forecast about -3.01 EPS for the fiscal year.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) had its price objective cut by equities researchers at Royal Bank Of Canada from $39.00 to $37.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Royal Bank Of Canada's price objective suggests a potential upside of 175.40% from the company's current price.

A number of other equities analysts have also weighed in on EYPT. Weiss Ratings reissued a "sell (d-)" rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, April 21st. Citigroup lifted their price target on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a "buy" rating in a report on Monday, March 9th. HC Wainwright boosted their price target on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday, March 5th. Finally, Chardan Capital raised their price objective on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 4th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $31.80.

Eyepoint Pharmaceuticals Trading Up 0.6%

NASDAQ:EYPT traded up $0.09 during trading hours on Thursday, hitting $13.44. 468,946 shares of the stock were exchanged, compared to its average volume of 1,212,979. Eyepoint Pharmaceuticals has a 52-week low of $5.30 and a 52-week high of $19.11. The firm's fifty day moving average price is $14.40 and its 200 day moving average price is $14.60. The company has a market cap of $1.13 billion, a P/E ratio of -4.25 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.79) by ($0.20). Eyepoint Pharmaceuticals had a negative net margin of 739.39% and a negative return on equity of 88.31%. The firm had revenue of $0.70 million during the quarter, compared to analysts' expectations of $0.35 million. Equities analysts expect that Eyepoint Pharmaceuticals will post -3.01 EPS for the current fiscal year.

Insider Activity at Eyepoint Pharmaceuticals

In other news, insider Ramiro Ribeiro sold 2,437 shares of Eyepoint Pharmaceuticals stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $15.00, for a total transaction of $36,555.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.46% of the company's stock.

Institutional Trading of Eyepoint Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Rhumbline Advisers raised its position in Eyepoint Pharmaceuticals by 11.0% in the second quarter. Rhumbline Advisers now owns 96,280 shares of the company's stock valued at $906,000 after purchasing an additional 9,548 shares during the period. American Century Companies Inc. raised its position in Eyepoint Pharmaceuticals by 57.8% in the second quarter. American Century Companies Inc. now owns 67,612 shares of the company's stock valued at $636,000 after purchasing an additional 24,752 shares during the period. Invesco Ltd. raised its position in Eyepoint Pharmaceuticals by 199.8% in the second quarter. Invesco Ltd. now owns 128,772 shares of the company's stock valued at $1,212,000 after purchasing an additional 85,824 shares during the period. Raymond James Financial Inc. raised its position in Eyepoint Pharmaceuticals by 11.0% in the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company's stock valued at $112,000 after purchasing an additional 1,177 shares during the period. Finally, Adage Capital Partners GP L.L.C. raised its position in Eyepoint Pharmaceuticals by 9.7% in the second quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company's stock valued at $63,988,000 after purchasing an additional 600,000 shares during the period. Hedge funds and other institutional investors own 99.41% of the company's stock.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.